Last reviewed · How we verify
Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)
2 different formulations and 4 different single doses of tafamidis will be compared. All subjects will receive both formulations and 3 different doses. Subjects will be fasted before taking the drug. After swallowing single dose of tafamidis, tafamidis blood concentrations will be measured periodically for 8 days. After another 16 days, all subjects will repeat the procedure twice, each time with the other formulation/dose.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 9 |
| Start date | Fri Sep 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy Volunteers
Interventions
- Tafamidis
Countries
Belgium